The American Society of Oncology (ASCO) 2021 Annual Meeting assembled leading experts to discuss new and exciting research. VJOncology had the chance the opportunity to interview speakers and get their perspectives on the latest progress within the field.
See our top editorial picks below, and more at VJOncology.com.
Scott Tagawa
VISION: 177Lu-PSMA-617 in PSMA-positive mCRPC
Evan Lipson
RELATIVITY-047: relatlimab and nivolumab in first-line advanced melanoma
Sébastien Perreault
Larotrectinib in patients with TRK fusion-positive primary CNS tumors
Patrick Schoffski
BOS172738 in RET-altered tumors
David Spigel
PACIFIC: durvalumab after chemoradiotherapy in unresectable stage III NSCLC
Guy Jerusalem
DESTINY-Breast01: trastuzumab deruxtecan in HER2+ breast cancer with brain metastases
